Ovid Therapeutics Reports Q3 GAAP EPS of -$0.10, Missing Estimates by $0.02
Ovid Therapeutics (OVID) reported third-quarter earnings that fell slightly short of analyst expectations. The company posted a GAAP earnings per share (EPS) of -$0.10, missing the consensus estimate by $0.02. Despite the earnings miss, the company maintains a solid liquidity position with $161.4 million in cash, cash equivalents, and marketable securities as of September 30, 2026. Management indicated that this capital provides a sufficient financial runway to support operations into 2029.
Tickers: $OVID
Topics: cash runway EPS miss financial results quarterly earnings
Read the full article at Seeking Alpha
Part of the story Sensei Biotherapeutics Reports Q3 GAAP EPS of -$0.79, Slightly Missing Estimates (8 articles)